Videos

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

Ridker joins to discuss some of his recent work, provide a deep dive into use of inflammatory biomarkers for identifying patients with residual inflammatory risk, provide perspective on use of MACE compared with all-cause mortality in cardiovascular clinical trials, and discuss the optimized uptake of SGLT2 inhibitors in care.

On Chen, MD, director of the Cardiac Intensive Care Unit and the Advanced Lipid Management Program at Stony Brook University, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into clinical processes at his institution and his perspective on some of the latest advances in lipid management.

In this episode of The Heart Team, which was recorded on-site at AHA 2022, Scott Solomon, MD, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into his experience as a trialist, use of newer medications, and what might be next for the heart failure community.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

Females generally have a lower risk of cardiovascular disease compared to males.

Patients with obesity have higher costs and longer hospital stays for IBD.

An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.

A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.

New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.

Up to 2% of patients with IBD also have EoE.

A discussion with the moderator of the Global Parents for Eczema Research symposium regarding climate change and the effects of fire, drought, airborne pollution on atopic dermatitis.

Guselkumab bested placebo in clinical results of patients with ulcerative colitis.

A discussion with Dr. Boos on the topic of climate change and airborne pollution exposure leading to or exacerbating atopic dermatitis.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

"The best test is the 1 that gets done," Williams said.

The common inherited condition autosomal dominant polycystic kidney disease (ADPKD) remains elusive when presented in primary care due to its nonspecific symptoms.

Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.

Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.

A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index

Dupilumab represents the first ever approved treatment for EoE.

If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.

The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.

During a recent interview regarding ReOpen1 and ReOpen2 trials, Dr. Mahmoud described a new treatment device for chronic rhinosinusitis patients.

The approval of risankizumab represents the first IL-23 approved for IBD.